3 Questions You Need to Ask Ahead of Johnson & Johnson's Third-Quarter Report
Healthcare conglomerate Johnson & Johnson (NYSE: JNJ) is what you might call a staple holding in many investors' portfolios. Its superior 2.5% dividend yield and 55-year streak of raising its payout has attracted a cadre of income investors, while an array of value, income, and growth investors have bought into the Johnson & Johnson thesis on the basis of its operational diversity.
J&J, as it's more commonly known, is comprised of three operating segments, each of which serves a purpose. Pharmaceuticals, which is J&J's largest segment by revenue generation, provides rapid growth and high margins. Meanwhile, medical devices provides a long-tail growth opportunity amid an aging global population, and consumer health products delivers strong pricing power and predictable cash flow.
Image source: Getty Images.
Source: Fool.com
Johnson & Johnson Stock
With 33 Buy predictions and 1 Sell predictions Johnson & Johnson is one of the favorites of our community.
As a result the target price of 195 € shows a positive potential of 43.21% compared to the current price of 136.16 € for Johnson & Johnson.
